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theOBJECTIVES The purpose of this study was to investigate the differential clinical outcomes after percutaneous coro-
nary intervention (PCI) for coronary bifurcation lesions with 1- or 2-stenting techniques using ﬁrst- or second-generation
drug-eluting stents (DES).
BACKGROUND The 2-stenting technique has been regarded to have worse clinical outcomes than the 1-stenting
technique after bifurcation PCI with ﬁrst-generation DES. However, there has been a paucity of data comparing the 1- and
2-stenting techniques with the use of second-generation DES.
METHODS Patient-level pooled analysis was performed with 3,162 patients undergoing PCI using ﬁrst- or second-
generation DES for bifurcation lesions from the “Korean Bifurcation Pooled Cohorts” (COBIS [Coronary Bifurcation
Stenting] II, EXCELLENT [Registry to Evaluate Efﬁcacy of Xience/Promus Versus Cypher in Reducing Late Loss After
Stenting], and RESOLUTE-Korea [Registry to Evaluate the Efﬁcacy of Zotarolimus-Eluting Stent]). The 3-year clinical
outcomes were compared between 1- and 2-stenting techniques, stratiﬁed by the type of DES.
RESULTS With ﬁrst-generation DES, rates of target lesion failure (TLF) or patient-oriented composite outcome (POCO)
(a composite of all death, any myocardial infarction, any repeat revascularization, and cerebrovascular accidents) at 3
years were signiﬁcantly higher after the 2-stenting than the 1-stenting technique (TLF 8.6% vs. 17.5%; p < 0.001; POCO
18.1% vs. 28.5%, p < 0.001). With second-generation DES, however, there was no difference between 1- and 2-stenting
techniques (TLF 5.4% vs. 5.8%; p ¼ 0.768; POCO 11.2% vs. 12.9%; p ¼ 0.995). The differential effects of 2-stenting
technique on the prognosis according to the type of DES were also corroborated with similar results by the inverse
probability weighted model. The 2-stenting technique was a signiﬁcant independent predictor of TLF in ﬁrst-generation
DES (hazard ratio: 2.046; 95% conﬁdence interval: 1.114 to 3.759; p < 0.001), but not in second-generation DES (hazard
ratio: 0.667; 95% conﬁdence interval: 0.247 to 1.802; p ¼ 0.425).
CONCLUSIONS Patient-level pooled analysis of 3,162 patients in Korean Bifurcation Pooled Cohorts demonstrated
that the 2-stenting technique showed comparable outcomes to 1-stenting technique with second-generation DES,
which is different from the results of ﬁrst-generation DES favoring the 1-stenting technique. (J Am Coll Cardiol Intv
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
DES = drug-eluting stent(s)
PCI = percutaneous coronary
intervention
POCO = patient-oriented
composite outcome
TLF = target lesion failure
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1319E ven with improvements in techniques andtechnologies, the coronary bifurcation lesionis still 1 of the most challenging lesion subsets
in the ﬁeld of percutaneous coronary intervention
(PCI). Among the several procedural steps, the most
important decision might be the choice between 1-
and 2-stenting strategies. Previously, the consensus
has been conﬂicting, but modestly favored the 1-
stenting technique with provisional side branch inter-
vention over the systemic 2-stenting technique for
bifurcation lesions (1). Following these results, the
current guidelines recommend a provisional strategy
with a 1-stenting technique only as an initial
approach for bifurcation lesions (Class I, Level ofSEE PAGE 1332Evidence: A from the ACCF/AHA/SCAI 2011 guideline
[2]; Class IIa, Level of Evidence: A from the ESC/
EACTS 2014 guideline [3]). However, these previous
results were all on the basis of studies using
ﬁrst-generation drug-eluting stents (DES). In real-
world practice, second-generation biocompatible or
biodegradable-polymer coated stents have replaced
ﬁrst-generation DES, and these DES have proven to
have better efﬁcacy and safety in nonbifurcation le-
sions (4). Thus, we can expect better results from
second-generation DES than the ﬁrst-generation
DES also in the bifurcation subset, even using
complicated strategies like the 2-stenting technique.
Whether the 2-stenting technique with the use of
second-generation DES will show comparable results
to the 1-stenting technique is still an elusive issue in
the ﬁeld of bifurcation PCI. Although few previous
studies (5,6) have tried to evaluate this issue, none
have shown a clear answer to this question, mainly
due to relatively small sample sizes.
Therefore, we sought to compare the 3-year clinical
outcomes following 1- or 2-stenting techniques with
the use of ﬁrst- or second-generation DES with a
patient-level pooled data from dedicated, large-scale,
real-world registries.
METHODS
Extended description of study methods are presented
in the Online Appendix.
POOLED PATIENT POPULATION. The analysis popu-
lation of this studywas the “Korean Bifurcation PooledHealth, Welfare & Family, Republic of Korea. The authors have reported that
this paper to disclose.
Manuscript received March 31, 2015; revised manuscript received April 28, 2Cohorts,”which includes 3 different registries
in Korea. First, the COBIS II (Coronary Bifur-
cation Stenting) registry (NCT01642992) is
a dedicated bifurcation PCI registry with the
use of ﬁrst- or second-generation DES. From
2003 through 2009, 2,897 consecutive pa-
tients were enrolled from 18 major coronary
intervention centers in Korea (7). The inclu-
sion criteria were: 1) coronary bifurcation
lesions treated with DES only; 2) main vessel
(MV) diameter of $2.5 mm and side branch (SB)
diameter of $2.3 mm conﬁrmed by quantitative coro-
nary angiography (QCA). Patients with cardiogenic
shock, who received cardiopulmonary resuscitation,
or who had protected left main (LM) disease were
excluded.
The EXCELLENT (Registry to Evaluate Efﬁcacy of
Xience/Promus Versus Cypher in Reducing Late Loss
After Stenting) (NCT00960648) and RESOLUTE-Korea
(Registry to Evaluate the Efﬁcacy of Zotarolimus-
Eluting Stent) (NCT00960908) registries were dedicated
second-generation DES registries for everolimus-
eluting stents (Xience V [Abbott Vascular, Santa
Clara, California]/Promus [Boston Scientiﬁc, Natick,
Massachusetts]) or zotarolimus-eluting Resolute stents
(Endeavor Resolute [Medtronic, Minneapolis, Min-
nesota]) that enrolled all-comers treated with $1
everolimus-eluting stent or zotarolimus-eluting Reso-
lute stent (3,056 patients in 29 centers and 1,998 pa-
tients in 25 participating centers, respectively) without
exclusions during the period of 2008 through 2010 (8).
Among the total 5,054 patients from the EXCELLENT
and RESOLUTE-Korea registries, 265 patients who met
the inclusion criteria of the COBIS II registry were
included in our analysis. These 265 patients met the
same inclusion and exclusion criteria and were
analyzed by the same bifurcation QCA system as the
COBIS II registry.
Therefore, the ﬁnal sample size of the Korean
Bifurcation Pooled Cohorts was 3,162 patients. Among
these patients, 2,475were treatedwithﬁrst-generation
DES and 687 were treated with second-generation
DES (Figure 1). Every patient in the Korean Bifurca-
tion Pooled Cohorts was followed for clinical out-
comesup to 3years (median follow-upduration 1,096.0
days, IQR: 778.8 to 1,497.0 days).
FOLLOW-UP, DATA COLLECTION, AND ANALYSIS.
Coronary angiograms were reviewed and analyzedthey have no relationships relevant to the contents of
015, accepted May 7, 2015.
FIGURE 1 Construction of Korean Bifurcation Pooled Cohorts for Patient-Level Pooled Analysis of 3,162 Patients
This study was a patient-level pooled analysis of the Korean Bifurcation Pooled Cohorts including 3 different registries. CVA ¼ cerebrovascular
accident; DES ¼ drug-eluting stent(s); EES ¼ everolimus-eluting stent(s); MI ¼ myocardial infarction; PCI ¼ percutaneous coronary inter-
vention; TLR ¼ target lesion revascularization; ZES-R ¼ zotarolimus-eluting Resolute stent(s).
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Samsung Medical Center (COBIS II registry) or Seoul
National University Hospital (EXCELLENT and
RESOLUTE-Korea registries). For the QCA, standard-
ized deﬁnitions for each segment of bifurcation lesion
(proximal MV, distal MV, and SB ostium) were used as
previously described (7). For any clinical events, all
relevant medical records were reviewed and adjudi-
cated by an external clinical event committee. Using
the Korean health system’s unique identiﬁcation
numbers, the vital status of 100% of patients was
crosschecked. The study protocol was approved by
the ethics committee at each participating center and
was conducted according to the principles of the
Declaration of Helsinki. All patients provided written
informed consent.
OUTCOMES AND DEFINITIONS. The primary out-
come was target lesion failure (TLF), a composite of
cardiac death, myocardial infarction (MI) (not clearly
attributed to a nontarget vessel), or a clinicallyindicated target lesion revascularization. The key
secondary outcome, the patient-oriented composite
outcome (POCO), included all-cause mortality, any
MI (including nontarget vessel territory), any revas-
cularization, and cerebrovascular accidents. All de-
aths were considered cardiac unless an undisputed
noncardiac cause was present. Other secondary out-
comes included individual components of TLF and
POCO, and stent thrombosis (ST), deﬁned as deﬁnite,
probable, or possible according to the Academic
Research Consortium (ARC) deﬁnitions.
STATISTICAL ANALYSIS. The main comparison
group was the 1-stenting versus 2-stenting technique,
and this comparison was stratiﬁed according to the
type of DES (ﬁrst- or second-generation). The analysis
was performed in 2 parts. First, analysis and com-
parison of primary and secondary clinical outcomes
between the 1- and 2-stenting techniques were con-
ducted in the original pooled patient population.
Second, the comparison of clinical outcomes was
TABLE 1 Baseline Clinical Characteristics
First-Generation DES (n ¼ 2,475) Second-Generation DES (n ¼ 687)
1-Stent
(n ¼ 1,802)
2-Stent
(n ¼ 673) p Value
1-Stent
(n ¼ 409)
2-Stent
(n ¼ 278) p Value
Demographics
Age, yrs 62.0  10.2 62.5  10.2 0.239 62.9  10.5 63.1  11.0 0.829
Age >65 yrs 706 (39.2) 281 (41.8) 0.244 181 (44.3) 130 (46.8) 0.517
Male 1,303 (72.3) 472 (70.1) 0.285 301 (73.6) 200 (71.9) 0.633
Coexisting conditions
Diabetes mellitus 509 (28.2) 207 (30.8) 0.220 133 (32.5) 94 (33.8) 0.723
Hypertension 1,032 (57.3) 388 (57.7) 0.864 257 (62.8) 177 (63.7) 0.700
Dyslipidemia 582 (32.3) 209 (31.1) 0.555 137 (33.5) 115 (41.4) 0.082
Peripheral vascular disease 25 (1.4) 12 (1.8) 0.470 3 (0.7) 4 (1.4) 0.366
Chronic kidney disease* 49 (2.7) 22 (3.3) 0.466 12 (2.9) 7 (2.5) 0.744
Cardiac risk factors
Current smoker 474 (26.3) 154 (22.9) 0.082 105 (25.7) 70 (25.2) 0.870
Previous myocardial infarction 106 (5.9) 55 (8.2) 0.040 12 (2.9) 22 (7.9) 0.003
Previous cerebrovascular event 121 (6.7) 51 (7.6) 0.452 24 (5.9) 16 (5.8) 0.944
Previous PCI 228 (12.7) 144 (21.4) <0.001 45 (11.0) 31 (11.2) 0.951
Previous CABG 17 (0.9) 11 (1.6) 0.148 2 (0.5) 3 (1.1) 0.372
Family history of CAD 54 (3.0) 13 (1.9) 0.146 19 (4.6) 22 (7.9) 0.189
LVEF, % 58.0  11.3 58.7  12.1 0.223 58.0  10.5 59.9  10.8 0.029
LVEF <50% 292 (19.6) 104 (19.4) 0.912 59 (16.0) 38 (15.5) 0.862
Clinical indication of PCI 0.002 0.058
Stable angina 662 (36.7) 222 (33.0) 143 (35.0) 107 (38.5)
Unstable angina 643 (35.7) 292 (43.4) 135 (33.0) 103 (37.1)
Acute myocardial infarction 456 (18.4) 139 (20.7)
NSTEMI 232 (12.9) 84 (12.5) 63 (15.4) 40 (14.4)
STEMI 224 (12.4) 55 (8.2) 61 (14.9) 20 (7.2)
Acute coronary syndrome 1,099 (61.0) 431 (64.0) 0.164 259 (63.5) 163 (58.6) 0.200
Silent ischemia 36 (2.0) 17 (2.5) 6 (1.4) 8 (2.9)
Complexity of CAD
Angiographic disease extent <0.001 <0.001
1VD 866 (48.1) 221 (32.8) 179 (43.8) 100 (36.0)
2VD 710 (39.4) 322 (47.8) 173 (42.3) 103 (37.1)
3VD 225 (12.5) 130 (19.3) 57 (13.9) 75 (27.0)
Left main disease 292 (16.2) 229 (34.0) <0.001 101 (24.7) 52 (18.8) 0.068
Bifurcation at left main 397 (22.0) 292 (43.4) <0.001 134 (32.8) 80 (28.8) 0.268
No. of stented lesions/patient 1.33  0.59 1.41  0.66 0.003 1.41  0.64 1.86  0.93 <0.001
No. of used stents 1.55  0.81 2.68  1.02 <0.001 1.68  0.92 2.62  1.28 <0.001
At least 1 ISR 55 (3.1) 44 (6.5) <0.001 14 (3.4) 8 (2.9) 0.690
Total occlusion of MV (pre-PCI) 178 (9.9) 41 (6.1) 0.003 59 (14.4) 22 (7.9) 0.009
Total occlusion of SB (pre-PCI) 72 (4.0) 30 (4.5) 0.607 23 (5.6%) 8 (2.9%) 0.089
Primary PCI 227 (12.6) 56 (8.3) 0.003 81 (19.9) 24 (8.6) <0.001
Maintaining DAPT after index PCI at last follow-up 635 (35.2) 375 (55.7) <0.001 191 (49.1) 139 (55.2) 0.134
Values are mean  SD or n (%). *Chronic kidney disease was deﬁned as the presence of kidney damage or estimated glomerular ﬁltration rate of <60 ml/min/1.73 m2 calculated
by the Cockcroft-Gault formula for <3 months, as with the Kidney Disease Outcomes Quality Initiative guidelines.
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; DAPT ¼ dual antiplatelet agent therapy; DES ¼ drug-eluting stent(s); ISR ¼ in-stent restenosis; LVEF ¼
left ventricular ejection fraction; MV ¼ main vessel; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; SB ¼ side branch;
STEMI ¼ ST-segment elevation myocardial infarction; VD ¼ vessel disease.
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1321repeated using an inverse probability weighted (IPW)
Cox proportional hazard regression model as well as
propensity score matching with a stratiﬁed Cox pro-
portional hazard regression model to adjust for un-
even distribution of baseline characteristics between
the 1- and 2-stenting techniques. In addition, an IPW
Cox proportional hazard model was used to identifyindependent predictors of the primary clinical
outcome, TLF, in each stratum according to type of
stent. C-statistics with 95% conﬁdence intervals (CIs)
were calculated to validate the discriminant function
of the model. To assess the effect of unmeasured
confounders, which could not be adjusted by IPW
analysis or propensity score matched analysis, we
TABLE 2 Angiographic and Procedural Characteristics
First-Generation DES (n ¼ 2,475) Second-Generation DES (n ¼ 687)
1-Stent
(n ¼ 1,802)
2-Stent
(n ¼ 673) p Value
1-Stent
(n ¼ 409)
2-Stent
(n ¼ 278) p Value
Vessel involved <0.001 0.268
LM bifurcation 397 (22.0) 292 (43.4) 134 (32.8) 80 (28.8)
LAD/Dg 1,040 (57.7) 326 (48.4) 201 (49.1) 152 (54.7)
LCX/OM 264 (14.7) 34 (5.1) 54 (13.2) 28 (10.1)
RCA bifurcation 101 (5.6) 21 (3.1) 20 (4.9) 18 (6.5)
SYNTAX score <0.001 0.259
Low (0–22) 1,417 (79.3) 417 (62.3) 309 (76.3) 200 (72.2)
Intermediate (23–32) 291 (16.3) 183 (27.4) 80 (19.8) 59 (21.3)
High ($33) 78 (4.4) 69 (10.3) 16 (4.0) 18 (6.5)
Medina classiﬁcation <0.001 <0.001
True bifurcation 798 (44.3) 506 (75.2) 178 (43.5) 190 (68.3)
1.1.1 496 (27.5) 318 (47.3) 117 (28.6) 108 (38.8)
1.0.1 139 (7.7) 48 (7.1) 22 (5.4) 23 (8.3)
0.1.1 163 (9.0) 140 (20.8) 39 (9.5) 59 (21.2)
Non-true bifurcation 1004 (55.7) 167 (24.8) 231 (56.5) 88 (31.7)
1.0.0 280 (15.5) 15 (2.2) 57 (13.9) 9 (3.2)
0.1.0 382 (21.2) 38 (5.6) 92 (22.5) 25 (9.0)
1.1.0 309 (17.1) 54 (8.0) 70 (17.1) 29 (10.4)
0.0.1 33 (1.8) 60 (8.9) 12 (2.9) 25 (9.0)
Stent type <0.001 <0.001
SES 992 (55.0) 422 (62.7) — —
PES 614 (34.1) 208 (30.9) — —
ZES-Splint 194 (10.8) 41 (6.1) — —
EES — — 356 (87.0) 120 (43.2)
ZES-Resolute — — 53 (13.0) 158 (56.8)
Others 2 (0.1) 2 (0.3) — —
Stenting techniques NA
1-stent technique 1,802 (100.0) — 409 (100.0) —
2-stent technique — 673 (100.0) — 278 (100.0)
T-stenting or TAP — 245 (36.4) — 147 (52.9)
Crush — 323 (48.0) — 98 (35.2)
Kissing or V-stenting — 87 (12.9) — 14 (5.0)
Culottes — 15 (2.2) — 16 (5.8)
Others — 3 (0.4) — 3 (1.1)
Side branch stenting strategy NA
Provisional 2-stenting — 219 (32.5) — 93 (33.5)
Elective 2-stenting — 454 (67.5) — 185 (66.5)
Other procedural characteristics
Side branch pre-dilation 370 (20.5) 136 (20.2) 0.859 76 (18.6) 129 (46.4) <0.001
Final kissing balloon inﬂation 602 (33.4) 570 (84.7) <0.001 148 (36.2) 225 (80.9) <0.001
IVUS guidance PCI 576 (32.0) 351 (52.2) <0.001 167 (40.9) 152 (55.1) <0.001
Rotablation used 2 (0.1) 3 (0.4) 0.099 0 (0.0) 0 (0.0) NA
Remote site intervention 463 (25.7) 219 (32.5) <0.001 112 (27.4) 95 (34.2) 0.057
Devices used
Main vessel
Total stent length, mm 28.9  12.3 29.7  12.4 0.136 27.3  12.3 30.4  14.3 0.003
Maximal stent diameter, mm 3.17  0.40 3.25  0.36 <0.001 3.26  0.46 3.15  0.82 0.027
Side branch
Total stent length, mm — 22.3  9.2 NA — 20.8  8.7 NA
Maximal stent diameter, mm — 2.91  0.37 NA — 2.85  0.36 NA
Adjunctive NC ballooning
MV 378 (21.0) 191 (28.4) <0.001 154 (37.7) 186 (66.9) <0.001
SB 137 (7.6) 111 (16.5) <0.001 87 (21.3) 168 (60.4) <0.001
Continued on the next page
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TABLE 2 Continued
First-Generation DES (n ¼ 2,475) Second-Generation DES (n ¼ 687)
1-Stent
(n ¼ 1,802)
2-Stent
(n ¼ 673) p Value
1-Stent
(n ¼ 409)
2-Stent
(n ¼ 278) p Value
Procedural outcomes
MV closure during PCI 75 (4.2) 22 (3.3) 0.308 24 (5.9) 12 (4.3) 0.370
SB closure during PCI 135 (7.5) 42 (6.2) 0.283 34 (8.3) 16 (5.8) 0.205
MV ﬁnal TIMI ﬂow grade <3 13 (0.7) 2 (0.3) 0.226 2 (0.5) 0 (0.0) 0.517
SB ﬁnal TIMI ﬂow grade <3 47 (2.6) 4 (0.6) 0.002 13 (3.2) 2 (0.7) 0.033
Procedural success
MV 1,772 (98.3) 669 (99.4) 0.042 402 (98.3) 273 (98.2) 0.932
SB 1,208 (67.0) 664 (98.7) <0.001 285 (69.7) 242 (87.1) <0.001
Values are n (%) or mean  SD.
Dg ¼ diagonal; EES ¼ everolimus-eluting stent(s); LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; LM ¼ left main; NC ¼ noncompliant; OM ¼ obtuse
marginal branch; PES¼ paclitaxel-eluting stent(s); SES¼ sirolimus-eluting stent(s); TAP¼ T and Protrusion; ZES¼ zotarolimus-eluting stent(s); other abbreviations as in Table 1.
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1323performed Bayesian modeling with internal valida-
tion data as an additional sensitivity analysis. All
probability values were 2-sided, and p < 0.05 was
considered statistically signiﬁcant.
RESULTS
PATIENT AND LESION CHARACTERISTICS OF THE
KOREAN BIFURCATION POOLED COHORTS. The base-
line characteristics of patients are shown in Table 1. Of
the 3,162 patients in the Korean Bifurcation PooledTABLE 3 Quantitative Coronary Angiographic Analysis
First-Generation DES (n ¼ 2,475)
1-Stent
(n ¼ 1,802)
2-Stent
(n ¼ 673)
Bifurcation angle, 58.8 (45.0–75.8) 60.6 (46.7–81.0)
Pre-intervention
MV RD, mm 3.0 (2.7 to 3.3) 3.0 (2.7 to 3.4)
SB RD, mm 2.4 (2.3 to 2.7) 2.4 (2.3 to 2.7)
MV MLD, mm 0.9 (0.6 to 1.3) 1.0 (0.7 to 1.4)
SB MLD, mm 1.5 (0.9 to 1.9) 1.0 (0.7 to 1.4)
MV diameter stenosis, % 68.1 (58.7 to 78.7) 66.2 (56.4 to 76.8
SB diameter stenosis, % 40.7 (22.9 to 59.1) 59.4 (46.9 to 71.5
MV lesion length, mm 15.8 (10.0 to 24.4) 17.4 (10.4 to 28.5
SB lesion length, mm 0.0 (0.0 to 5.2) 8.3 (4.1 to 15.4)
Post-intervention
MV RD, mm 3.0 (2.8 to 3.3) 3.1 (2.8 to 3.5)
SB RD, mm 2.4 (2.3 to 2.7) 2.5 (2.3 to 2.8)
MV MLD, mm 2.6 (2.3 to 2.9) 2.7 (2.4 to 3.0)
SB MLD, mm 1.5 (1.1 to 2.0) 2.3 (2.0 to 2.6)
MV residual stenosis, % 14.2  13.2 14.4  11.1
SB residual stenosis, % 39.9  22.9 8.2  15.5
MV acute gain, mm 1.7 (1.3 to 2.1) 1.6 (1.3 to 2.0)
SB acute gain, mm 0.03 (0.29 to 0.32) 1.3 (1.0 to 1.6)
Values are median (interquartile range) or mean  SD.
MLD ¼ minimum lumen diameter; RD ¼ reference diameter; other abbreviations as inCohorts, 2,475 patients (78.3%) were treated with ﬁrst-
generation DES, whereas the remaining 687 (21.7%)
patients were treated with second-generation DES.
Among the patients in the ﬁrst-generation DES stra-
tum, 1,802 (72.8%) and 673 (27.2%) patients were
treated with the 1- and 2-stenting techniques, respec-
tively. In the second-generation DES stratum, 409
(59.5%) and 278 (40.5%) patients were treated with the
1- and 2-stenting techniques, respectively. The pro-
portion of true bifurcation (Medina 1,1,1; 1,0,1; or 0,1,1)
were higher in the 2-stenting group in both strata ofSecond-Generation DES (n ¼ 687)
p Value
1-Stent
(n ¼ 409)
2-Stent
(n ¼ 278) p Value
0.032 60.0 (47.0–78.5) 58.0 (44.8–75.0) 0.144
0.097 3.1 (2.8 to 3.4) 3.0 (2.7 to 3.3) 0.013
0.701 2.5 (2.3 to 2.8) 2.4 (2.2 to 2.7) 0.003
0.001 1.0 (0.6 to 1.4) 1.1 (0.7 to 1.5) 0.023
<0.001 1.5 (1.0 to 2.0) 0.9 (0.6 to 1.3) <0.001
) 0.002 67.0 (57.5 to 78.8) 65.1 (53.5 to 74.8) 0.004
) <0.001 39.5 (20.4 to 59.2) 64.2 (49.3 to 73.8) <0.001
) 0.009 15.6 (10.0 to 22.7) 20.3 (12.9 to 28.9) <0.001
<0.001 2.0 (0.0 to 6.7) 7.7 (4.8 to 15.2) <0.001
0.046 3.1 (2.8 to 3.5) 3.0 (2.7 to 3.3) 0.002
0.003 2.5 (2.3 to 2.8) 2.5 (2.2 to 2.8) 0.165
0.298 2.7 (2.4 to 3.0) 2.6 (2.3 to 2.9) 0.018
<0.001 1.6 (1.0 to 2.1) 2.1 (1.6 to 2.5) <0.001
0.740 11.9 (5.0 to 20.1) 11.7 (5.9 to 19.8) 0.923
<0.001 37.1 (21.6 to 55.4) 16.3 (4.5 to 31.2) <0.001
0.007 1.7 (1.3 to 2.1) 1.5 (1.2 to 1.9) <0.001
<0.001 0.02 (0.28 to 0.31) 1.1 (0.5 to 1.6) <0.001
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1324DES. Final kissing balloon inﬂation (FKI) in the
2-stenting group was performed in 84.7% of the ﬁrst-
generation DES stratum or 80.9% of the second-
generation DES stratum (Table 2). Other procedural
and angiographic characteristics are shown in
Table 2. Regardless of the type of DES, SB lesions
in QCA were signiﬁcantly longer and more stenotic
in the 2-stenting group (Table 3). In addition, post-
interventional residual percent diameter stenosis in
SB was signiﬁcantly milder in the 2-stenting group
(Table 3). When comparing patients enrolled in
the COBIS II and EXCELLENT/RESOLUTE-Korea reg-
istries, the patients enrolled from the EXCELLENT
and REOLUTE-Korea registries showed more severe
risk factor proﬁles, higher SYNTAX scores, higher
proportion of true bifurcation lesions, and more usage
of 2-stenting techniques (Online Tables 1 and 2).
CLINICAL OUTCOMES BETWEEN 1- VERSUS 2-STENTING
TECHNIQUES USING FIRST- OR SECOND-GENERATION
DES. In the ﬁrst-generation DES stratum, the inci-
dence of TLF was signiﬁcantly higher in the 2-stenting
technique group compared with the 1-stenting tech-
nique group (8.6% vs. 17.5%; hazard ratio [HR]:
2.08; 95% CI: 1.64 to 2.64; p < 0.001), mainly
driven by higher incidences of MI and TLR. In the
second-generation DES stratum, however, TLF was
comparable between the 2 groups (5.4% vs. 5.8%;
HR: 0.91; 95% CI: 0.47 to 1.74; p ¼ 0.659), along with
similar rates ofMI and TLR. The POCO showed a similar
trend to that of TLF; POCO was signiﬁcantly higher in
the 2-stenting technique group of the ﬁrst-generation
DES stratum, but was comparable between the 1- and
2-stenting technique groups in the second-generation
DES stratum (Table 4, Figure 2). The individual com-
ponents of TLF are presented in Figure 3.
The results of the IPW Cox proportional hazard
model comparing clinical outcomes between the
1- and 2-stenting techniques in each DES stratum
showed a similar trend with the unadjusted results;
there was no difference in clinical outcomes after the
1- and 2-stenting technique in second-generation DES
(Table 4, Figure 4).
The rates of ARC-deﬁned deﬁnite or probable ST
were signiﬁcantly higher in the 2-stenting group us-
ing ﬁrst-generation DES even after the adjustment of
baseline differences (IPW adjusted HR: 3.77; 95% CI:
1.95 to 7.28; p < 0.001). With the use of second-
generation DES, however, there was no difference of
ST between the 1- and 2-stenting techniques (IPW
adjusted HR: 1.60; 95% CI: 0.47 to 5.48; p ¼ 0.451).
The comparison of clinical outcomes in the pro-
pensity score-matched population showed similar
results to the IPW Cox proportional hazard model
(Online Tables 3 and 4). The results from the Bayesian
FIGURE 2 Cumulative Incidence of TLF or POCO After 1- Versus 2-Stent Technique Using First- or Second-Generation DES
Kaplan-Meier Curves are shown for each outcome and type of drug-eluting stent (DES) strata combination: (A and B) target lesion failure (TLF)
and (C and D) patient-oriented composite outcome (POCO) in ﬁrst- and second-generation DES. HR ¼ hazard ratio.
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1325analysis to assess the impact of unmeasured con-
founders were consistent with the original unadjusted
analysis, inverse probability weighted analysis, and
propensity score matched analysis, suggesting a
robustness of the results (Online Table 5).
In addition, there was no difference regarding the
rates of TLF or POCO among various 2-stenting tech-
niques (T-stenting, crush, culotte, kissing, or V-stent-
ing), regardless of DES type (Online Table 6).
RESTENOSIS PATTERN IN LEFT MAIN BIFURCATION
SUBGROUP AFTER 1- VERSUS 2-STENTING TECHNIQUE
USING FIRST- OR SECOND-GENERATION DES. Among
the total population, 27.8% (n ¼ 689) and 31.1% (n ¼
214) of patients were treated for LM bifurcation le-
sions in the ﬁrst- and second-generation DES stratum,
respectively (Table 2). Through the 3-year follow-up
period, the incidence of TLR in LM bifurcation
was 10.7% (ﬁrst-generation DES stratum, 74 of 689
patients) and 5.6% (second-generation DES stratum,
12 of 214 patients). The incidence of TLR was signiﬁ-
cantly reduced with second-generation DES com-
pared with ﬁrst-generation DES (p ¼ 0.025).The patterns of TLR sites in MV and SB were mark-
edly different between the ﬁrst- and second-
generation DES stratum, and the locations of TLR site
in LM bifurcation are shown in Figure 5. In the
ﬁrst-generation DES stratum, the main restenosis site
was the proximal MV after the 1-stenting technique
compared with the SB after the 2-stenting technique.
In the second-generation DES stratum, however,
restenosis mainly occurred at SB after 1-stenting
whereas it occurred evenly and rarely both at the MV
and SB (Figure 5).
In addition, the rates of TLR were also different
between the 1- and 2-stenting techniques according to
the type of DES. In ﬁrst-generation DES, the 2-stenting
technique showed signiﬁcantly higher rates of TLR
than 1-stenting (5.5% vs. 17.8%; p < 0.001). However,
therewas no difference in TLR rates between the 1- and
2-stenting techniques in second-generation DES (6.7%
vs. 3.8%; p ¼ 0.361) (Figure 5).
INDEPENDENT PREDICTORS FOR TARGET LESION
FAILURE ACCORDING TO TYPE OF STENTS.
Independent predictors for 3-year TLF are presented
FIGURE 3 Cumulative Incidence of Individual Components of TLF After 1- Versus 2-Stent Technique Using First- or Second-Generation DES
(A to C) Individual components of target lesion failure in ﬁrst-generation DES. (D to F) Individual components of target lesion failure in second-
generation DES. Abbreviations as in Figure 2.
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1326in Table 5. The 2-stenting technique was signiﬁcantly
associated with higher incidence of TLF in the
ﬁrst-generation DES stratum (HR: 2.046; 95% CI:
1.114 to 3.759; p ¼ 0.021), but not in the second-
generation DES stratum (HR: 0.667; 95% CI: 0.247
to 1.082; p ¼ 0.425). Unlikely from the results of
ﬁrst-generation DES, LM bifurcation was still an inde-
pendent predictor for TLF in the second-generation
DES stratum. In terms of anatomical factors, MV
reference diameter was a protective factor in ﬁrst-
generation DES, whereas SB minimum lumen diam-
eter was a protective factor in second-generation DES.
Both models showed an acceptable range of discrimi-
nant function (Table 5).
DISCUSSION
A patient-level pooled analysis of 3,162 patients in the
Korean Bifurcation Pooled Cohorts, which explored
3-year clinical outcomes following 1- or 2-stenting
techniques using ﬁrst- or second-generation DES, has
demonstrated: 1) the 2-stenting technique showed
signiﬁcantly worse TLF or POCO than the 1-stenting
technique using ﬁrst-generation DES; 2) however, the2-stenting technique using second-generation DES
showed comparable results up to 3-year follow-upwith
the 1-stenting technique; 3) the rate of ARC-deﬁned
deﬁnite or probable ST was signiﬁcantly higher after
the 2-stenting techniquewithﬁrst-generationDES, but
there was no difference between the 1- and 2-stenting
techniques using second-generation DES; 4) the 2-
stenting technique was an independent predictor of
TLF only in the ﬁrst-generation DES group; and 5) in
the real-world practice of bifurcation PCI with second-
generation DES, all independent predictors were
patient-related comorbidities, without any procedure-
related factors such as 1- or 2-stenting technique.
AN OLD PARADIGM REGARDING THE 2-STENTING
STRATEGY IN THE FIRST-GENERATION DES ERA.
Although there have been some conﬂicting results,
previous studies comparing a 1- and 2-stenting strat-
egy showed worse clinical outcomes after the
2-stenting strategy using ﬁrst-generation DES. There
have been 6 randomized controlled trials (RCTs)
(9–14), and these studies showed a tendency toward
worse clinical outcomes in the 2-stenting group
compared with the 1-stenting group, mainly driven by
FIGURE 4 Inverse Probability Weighted Comparison of Clinical Outcomes
The inverse probability weighted hazard ratio of the 2-stenting compared with 1-stenting technique in (A) ﬁrst-generation DES or in (B) second-
generation DES are presented. CI ¼ conﬁdence interval; IPW ¼ inverse probability weighted; other abbreviations as in Figure 2.
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1327MI (15). A patient-level pooled analysis of the NORDIC
and BBC-ONE (British Bifurcation Coronary Study:
Old, New, and Evolving strategies) trials reported that
at 9 months, the incidence of the composite endpoint
of all-cause mortality, MI, and target vessel revascu-
larization (TVR) was signiﬁcantly higher in the com-
plex PCI group with a 2-stenting technique than the
simple PCI group (10.1% vs. 17.3% in simple vs. com-
plex group; HR: 1.84; 95% CI: 1.28 to 2.66; p ¼ 0.001)
(16). In addition, the meta-analysis of Zhang et al. (17)
also reported worse outcomes for the complex group
due to a signiﬁcantly higher incidence of periproce-
dural MI and MI occurring at follow-up. On the basis of
these results, the current guidelines recommend a
provisional strategy of 1-stenting technique in MV
only as an initial approach for bifurcation lesions.
However, these previous results do not reﬂect
the current real-world practice, because ﬁrst-
generation DES are no longer used. Although second-
generation DES are shown to have superior efﬁcacy
and safety to ﬁrst-generation DES (4), most RCTs or
meta-analyses comparingﬁrst- and second-generation
DES could not represent the patients with bifurcation
lesions, because the proportion of bifurcation lesions
was generally <20% of the enrolled patients, even in
the all-comers RCT: 17% in COMPARE (Comparison ofthe everolimus eluting XIENCE-V stent with the
paclitaxel eluting TAXUS LIBERTE stent in all-comers:
a randomized open label trial), 12.5% in SORT OUT IV
(Scandinavian Organization for Randomized Trials
With Clinical Outcome IV), and 10.8% in the EXCEL-
LENT (Efﬁcacy of Xience/Promus Versus Cypher to
Reduce Late Loss After Stenting) trial (18–20). There-
fore, we need more evidence regarding the perfor-
mance of second-generation DES in the treatment of
bifurcation lesions, especially the results of the 2-
stenting technique.
AN EVOLVING PARADIGM REGARDING SYSTEMIC
2-STENTING STRATEGY WITH SECOND-GENERATION
DES. There have been 5 reports comparing 1- with 2-
stenting techniques using second-generation DES,
which showed vast discrepancies across studies
(5,6,15,21–23). In the subgroup analysis from the
RESOLUTE ALL COMERS trial, 382 patients received
bifurcation PCI (310 treated with the provisional
approach and 82 treated by systemic 2-stenting) (6). At
2-year follow-up, TLF rates were numerically but not
statistically higher in those receiving the 2-stenting
technique, mainly due to signiﬁcantly higher rates of
target-vessel MI, which were mostly periprocedural.
The bifurcation substudy of the SPIRIT V (A Clinical
Evaluation of the XIENCE V Everolimus Eluting
FIGURE 5 TLR Locus in Left Main Bifurcation Subset
The number of TLR locations was presented with dots after a 1- or 2-stenting strategy using ﬁrst- or second-generation DES. If multiple sites of
TLR occurred, both sites were marked with dots according to the type of DES. ISR ¼ in-stent restenosis; LM ¼ left main; other abbreviations as
in Figure 1.
TABLE 5
Treated W
First-gene
Periphe
Previou
Previou
Systemi
True bif
Main ve
Main ve
Second-ge
Periphe
Chronic
Left ma
Side bra
Systemi
*C-index of
0.673) and
bifurcation
CVA ¼ ce
Lee et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 0 , 2 0 1 5
First- and Second-Generation DES in Bifurcation PCI A U G U S T 2 4 , 2 0 1 5 : 1 3 1 8 – 3 1
1328Coronary Stent System in the Treatment of Patients
With de Novo Coronary Artery Lesions) registry
showed that those who underwent stent implantation
(n ¼ 90) into the SB (and who thus ultimately had
received the 2-stenting technique) showed a higher
incidence of TLR (6.9% vs. 0.6%; log rank p ¼ 0.0028),
compared with those receiving simple balloon inﬂa-
tion (24,25). These 2 studies suggest that, similar to theIndependent Predictors of Target Lesion Failure in Patients
ith First- or Second-Generation Stents*
Adjusted HR 95% CI p Value
ration DES (n ¼ 2,475)
ral artery disease 3.955 2.045–7.650 <0.001
s CABG 3.922 1.822–8.442 <0.001
s CVA 2.326 1.577–3.432 <0.001
c 2-stenting technique 2.046 1.114–3.759 0.021
urcation† 1.797 1.204–2.681 0.004
ssel length, mm 1.014 1.004–1.024 0.008
ssel RD, mm 0.404 0.297–0.550 <0.001
neration DES (n ¼ 687)
ral artery disease 6.358 1.232–32.80 0.027
renal failure 3.539 1.257–9.964 0.017
in bifurcation 3.525 1.746–7.116 <0.001
nch MLD, mm 0.581 0.357–0.943 0.028
c 2-stenting technique 0.667 0.247–1.802 0.425
the inverse probability weighted Cox proportional hazard model was 0.638 (0.603 to
0.773 (0.687 to 0.860) for a model of ﬁrst- and second-generation DES. †True
denotes bifurcation lesions with Medina 1,1,1; 1,0,1; or 0,1,1.
rebrovascular accident; other abbreviations as in Tables 1, 3, and 4.data from ﬁrst-generation DES, 2-stenting results are
worse than the 1-stenting technique evenwith second-
generation DES. In contrast, some studies reported at
least a trend toward favorable outcomes of the
2-stenting technique (5,23). The DKCRUSH-II (Double
Kissing Crush versus Provisional Stenting Technique
for Treatment of Coronary Bifurcation Lesions) trial,
exclusively using the everolimus-eluting bio-
absorbable stent (EXCEL stent, JW Medical System,
Weihai, China), randomly assigned 370 patients with
true bifurcation lesions (Medina 1,1,1 or 0,1,1) to
either the double kissing double crush technique or
provisional 1-stenting technique (21). The rates of
TLR (4.3% vs. 13.0%; p¼0.005) or TVR (6.5% vs. 14.6%;
p ¼ 0.017) were signiﬁcantly lower in the 2-stenting
groups at 12-month follow-up, whereas the incidence
of major adverse cardiovascular events, MI, and deﬁ-
nite or probable ST were comparable between the 2
groups. The Nordic-Baltic Bifurcation Study IV, which
randomly assigned 450 patients to the 2- or 1-stenting
group, also showed similar trends with numerically
lower but statistically insigniﬁcant rates of major
adverse cardiovascular events (cardiac death, non-
procedural MI, TLR, or deﬁnite ST), TLR, or TVR at 6
months in the 2-stenting technique groups (5).
Although there may be several reasons for the dis-
crepancies across different studies, a relatively small
number of patients and substantial proportion of non–
true bifurcation lesion without any disease in the SB
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1329might be potential confounders that diluted the true
differences between 2 different stenting strategies. In
this regard, we demonstrated longer-term clinical
outcomes from the Korean Bifurcation Pooled Cohort,
the largest sample size of an unrestricted population
that reﬂects real-world practice of bifurcation PCI.
It should be noted that even bifurcation lesions
with the same Medina classiﬁcation can signiﬁcantly
differ with regard to ostial SB lesion severity, SB
lesion length, angulation between MV and SB, SB
size, and the corresponding myocardial territory (22).
This fact implies that the treatment strategy should
be individualized in every patient with bifurcation
lesions, and that universal application of provisional
1-stenting approach should be reconsidered. The
comparable outcomes of the 2- and 1-stenting tech-
nique with second-generation DES may support the
complete coverage of the lesion, especially in case of
the subtended myocardial territory of the SB is suf-
ﬁciently large, rather than the effort to minimize
metallic burden due to fear of delayed endotheliali-
zation and subsequent detrimental events, which
were mainly observed in ﬁrst-generation DES.
Some important factors that may have contributed
to improved clinical outcomes with the 2-stenting
technique should be considered. There has been
mounting evidence that contemporary techniques
improved clinical outcomes in bifurcation PCI. Main
technical advances include the use of proximal opti-
mization technique (POT), noncompliant (NC) balloon
for FKI, intravascular ultrasound-guided PCI, or
mandatory FKI in the 2-stenting technique (23,26). In
the current study, we observed a substantial increase
of adjunctive NC ballooning after the 2-stenting
technique using second-generation DES (28.4% in
the ﬁrst-generation DES group vs. 66.9% in the
second-generation DES group). Although the exact
proportion of POT among cases with adjunctive NC
ballooning in the main vessel could not be assessed
due to the missing data of POT performance in each
registry, the increased proportion of adjunctive NC
ballooning in the main vessel suggests the increased
use of POT as well. These technical advances might be
another important factor in the improvement of
clinical outcomes after the 2-stenting technique, be-
sides the use of second-generation DES.
In addition, most of the independent predictors for
TLF in second-generation DES were patient or lesion-
related factors, such as peripheral artery disease,
chronic renal failure, or LM bifurcation lesion, but not
device or procedural techniques. This result empha-
sizes the importance of general medical treatment for
comorbidities and optimal patient or lesion selection
for the success of bifurcation PCI.In this regard, it should be noted that LM bifurca-
tion lesions are still a signiﬁcant predictor for TLF
even with the use of second-generation DES. The
distal LM bifurcation lesion has shown worse clinical
outcomes than ostial or shaft lesions (27). There are
some possible explanations for the signiﬁcant prog-
nostic effect of LM bifurcation lesions even in second-
generation DES. First, this is a result of the clinical
importance and relatively lower threshold of repeat
revascularization of SB in LM bifurcation lesions.
Another factor is the unique anatomic feature of
LM bifurcation lesions. It is difﬁcult to accurately
assess the segment and conduct optimal revasculari-
zation of the LM lesion due to several factors, such as
its short length, the presence of overlapping daughter
branches, the concealment of diffuse atherosclerosis
due to arterial remodeling, the distinct lack of a
reference segment, and reverse tapering pattern of
the LM lesion (26). In addition, LM bifurcation lesions
usually showed a wider bifurcation angle, which has
been shown to be an independent predictor of major
adverse cardiac events, especially in the crush or
culotte stenting, whereas no such association was
observed in the 1-stenting technique group (28).
Indeed, the bifurcation angle was signiﬁcantly wider
in LM bifurcation lesions compared with non-LM
bifurcation lesions, regardless of 1- or 2-stenting
technique or ﬁrst- or second-generation DES group
in the current study (83.1  27.4 vs. 56.5  18.9;
p < 0.001). This geometric uniqueness of LM bifur-
cation lesions might be 1 potential explanation of why
the LM lesion is an independent predictor of TLF in
second-generation DES. Whether the second- or
third-generation DES will improve the outcome
after distal LM bifurcation PCI compared with CABG is
still unknown. Currently, 2 large ongoing trials
(EXCEL [Evaluation of Xience Prime versus Coronary
Artery Bypass Surgery for Effectiveness of Left
Main Revascularization] [NCT01205776] and NOBLE
[Nordic-Baltic-British Left Main Revascularization]
[NCT01496651]) would clarify this issue.
STUDY LIMITATIONS. First, the inherent limitations
of nonrandomized comparisons such as allocation bias
and uneven distribution of risk factors should be
considered. Although an inverse probability weighted
Cox regression model was used to adjust the baseline
differences, and the results from the Bayesian analysis
were consistent with the original analysis, unmea-
sured variables such as improvements in bifurcation
PCI technique (i.e., POT, general medical treatment)
and other potential confounders could not be
completely controlled. Second, the incidences of
clinical events, especially MI, were relatively lower
than in previous studies on bifurcation PCI. Although
PERSPECTIVES
WHAT IS KNOWN? The 2-stenting technique has
shown worse clinical outcomes than the 1-stenting
technique after bifurcation PCI with ﬁrst-generation
DES. In real-world practice, second-generation
biocompatible or biodegradable polymer-coated stents
have replaced ﬁrst-generation DES; however, there has
been a paucity of data comparing 1- and 2-stenting
techniques with the use of second-generation DES. A
patient-level pooled analysis of 3,162 patients in the
Korean Bifurcation Pooled Cohorts demonstrated the
differential prognostic effect of a 2-stenting strategy
between ﬁrst- and second-generation DES.
WHAT IS NEW? The 2-stenting technique using
second-generation DES showed comparable clinical
outcomes, including stent thrombosis, target lesion
revascularization, myocardial infarction, and mortal-
ity, up to 3-year follow-up compared with the
1-stenting technique.
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1330the possibility of under-reporting of the events cannot
be ignored, it has been consistently reported that the
incidence of MI is substantially lower in Asian pop-
ulations than in Western populations (14,20,29).
Third, it should be noted that the proportion of FKIwas
relatively lower in the 2-stenting technique using ﬁrst-
generation DES (84.7%) or 2-stenting with second-
generation DES (80.9%) than in previous trials such
as BBK (Bifurcations Bad Krozingen) (100%), CACTUS
(Coronary Bifurcations: Application of the Crushing
Technique Using Sirolimus-Eluting Stents) (92%),
or DKCRUSH-II (100%), which compared 1- and
2-stenting strategies. Optimal FKI is mandatory,
especially in the 2-stenting strategy (25). However,
because there was no statistical difference regarding
the proportion of FKI in the 2-stenting technique group
between ﬁrst- and second-generation DES, the con-
founding effect should be minimal. Fourth, we mainly
focused on the comparison of clinical outcomes after
bifurcation PCI with the 1- or 2-stenting technique.
Although the operator decided the provisional
1-stenting strategy for the bifurcation PCI, additional
implantation of a stent in SB is sometimes required.
Among the total 3,162 patients, 8.2% (n ¼ 260) were
treated with the 2-stenting technique in spite of an
initial decision of provisional 1-stenting strategy. We
incorporated these patients into the 2-stenting group
to clarify the differences of clinical outcomes between
1- and 2-stenting techniques. The incorporation of
these patients to the 1-stenting technique group as
initially assigned did not alter the overall results
presented in the paper. Last, we could not evaluate
the procedural time, radiation dose, and amount
of contrast agents used. Although 2-stenting with
second-generation DES showed comparable outcomes
to the 1-stenting technique, the operator should
consider the risk-beneﬁt ratio related to a successful
procedure and complete lesion coverage versus
increased radiation and contrast dose when using the
2-stenting procedure.WHAT IS NEXT? Such an improved performance of
second-generation DES, even after a complex tech-
nique for bifurcation lesions, may provide room for a
more aggressive approach for the selected bifurcation
lesions with appropriate anatomy and sufﬁciently
large subtended myocardium supplied by SB, rather
than universal application of the 1-stenting strategy.CONCLUSIONS
Our patient-level pooled analysis of 3-year clinical
results from 3,162 patients in the Korean Bifurcation
Pooled Cohorts demonstrated that the 2-stenting
technique showed comparable outcomes to a 1-stenting
technique with second-generation DES, which isdifferent from the results of ﬁrst-generation DES that
favored the 1-stenting technique. Such an improved
performance of second-generation DES, even after a
complex technique for bifurcation lesions, may pro-
vide room for a more aggressive approach for the
selected bifurcation lesions with appropriate anatomy
and sufﬁciently large subtendedmyocardium supplied
by SB, rather than universal application of the
1-stenting strategy.
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